[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"University of Campinas, Brazil\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":216},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,7,0,[8,47,74,106,135,163,189],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":30,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":41,"leadSponsor":43,"locationsCount":46},"100650050","phase-1-pharmacokinetics-of-zoledronic-acid-in-patients-on-dialysis-100650050",false,"NCT07741136","Pharmacokinetics of Zoledronic Acid in Patients on Dialysis","Pharmacokinetics of Zoledronic Acid in Patients With Chronic Kidney Disease on Dialysis","ZADIAL","Inclusion Criteria:\n\n* Individuals aged 18 years or older, with CKD-associated osteoporosis\n* eGFR ≥ 35 mL\u002Fmin\u002F1.73 m2 and advanced CKD on dialysis\n* Agree to participate in the research by signing the informed consent form\n\nExclusion Criteria:\n\n* Individuals under 18 years of age, pregnant or breastfeeding women\n* Patients with CKD with hypocalcemia\u002Fhypophsphatemia\n* Patients with CKD on dialysis with residual diuresis\\*\n* Patients with CKD on low-flux membrane dialysis\\*\n* Patients with neoplasia\n* Hypersensitivity to bisphosphonates, or previous use of the medication\n* Inadequate oral condition or anticipated invasive dental procedure within the next 12 months\n* Alkaline phosphatase \\\u003C 98 IU\u002FL or \\> 180 IU\u002FL\\*\n* PTH \\\u003C 130 pg\u002FmL and \\> 585 pg\u002FmL\\*\n* Severe liver disease\n* Severe heart disease\n* Clinical suspiction of osteomalacia\n* Cytopenias, defined as: platelets \\\u003C 120,000\u002Fmm³, neutrophils \\\u003C 3,000\u002Fmm³, lymphocytes \\\u003C 1,000\u002Fmm³ and hematocrit \\\u003C 26% \\* Applicable only to the group of patients undergoing dialysis.","ALL","18 Years",{"count":20,"type":21},24,"ESTIMATED","INTERVENTIONAL",[24],"PHASE1","Osteoporosis is a frequent complication of chronic kidney disease (CKD) on dialysis, with an estimated prevalence of approximately 40%. It is associated with increased fracture risk, reduced quality of life, and higher mortality. Despite available therapies, management often remains suboptimal, partly due to limited evidence on the safety and pharmacokinetics of bisphosphonates in this population. Objectives: To understand the pharmacokinetics of zoledronic acid in CKD patients on dialysis, as well as to analyze its effects on biomarkers of bone metabolism, bone mineral density (BMD), and clinical outcomes. Materials and Methods: This prospective clinical study involves 24 adult individuals, 8 with CKD-associated osteoporosis (control group; estimated glomerular filtration rate (eGFR) ≥ 35 mL\u002Fmin\u002F1.73 m²) and 16 with CKD-associated osteoporosis anuric on dialysis patients. Individuals undergoing dialysis will be assigned to receive zoledronic acid at doses of 2.5 mg or 5 mg intravenously (single dose, at the beggining of dialysis session), while patients with CKD-associated osteoporosis (control group; estimated glomerular filtration rate (eGFR) ≥ 35 mL\u002Fmin\u002F1.73 m²) will receive 5 mg, also in a single dose. Serial blood samples will be collected after infusion, during dialysis session and again up to 96h after dialysis session initiation. The dialysate will be continuously sampled in a tank and aliquots collected for further analysis. The plasma levels of zoledronic acid will be calculated from blood and dialysate samples using liquid chromatography mass spectrometry. The primary outcome is the plasma concentration-time curve of zoledronic acid during a regular dialysis session. Secondary outcomes are: (i) plasma concentration of zoledronic acid up to 96h;(ii) the total mass of zoledronic acid extracted by the dialysate; (iii) the dialytic clearance of zoledronic acid. Evaluation of bone biomarkers (e.g., PTH, alkaline phosphatase, calcium, phosphorus, CTX, and P1NP) and BMD (assessed by bone densitometry) will be performed at baseline and at 12 months. The study will be conducted at the UNICAMP Clinical Hospital, with the participation of one participating center, subject to prior approval from the respective Research Ethics Committees. All participants will be included only after signing the Informed Consent Form. Data will be anonymized and processed in accordance with the General Data Protection Law (LGPD). Expected results: To characterize the pharmacokinetic profile and establish the best dosage regimen of zoledronic acid in patients with CKD on dialysis; to observe the impact of the drug on biomarkers of bone metabolism and BMD.",[27,28,29],"Chronic Kidney Disease","Osteoporosis","Dialysis",[31,32,29,33,28],"Zoledronic acid","bisphosphonate","Pharmacokinetics","NOT_YET_RECRUITING","2026-07-31",{"date":37,"type":38},"2026-08-03","ACTUAL",{"date":40,"type":21},"2026-08-15",{"date":42,"type":21},"2028-08-15",{"name":44,"class":45},"University of Campinas, Brazil","OTHER",1,{"id":48,"slug":49,"hasResults":11,"nctId":50,"briefTitle":51,"officialTitle":52,"acronym":53,"eligibilityCriteria":54,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":55,"targetDuration":4,"studyType":57,"phases":4,"briefSummary":58,"conditions":59,"keywords":63,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":66,"lastUpdatePostDateStruct":67,"startDateStruct":69,"completionDateStruct":71,"leadSponsor":73,"locationsCount":46},"100648459","structural-and-clinical-predictors-of-cognitive-impairment-after-surgical-treatment-for-ruptured-cerebral-aneurysms-100648459","NCT07723131","Structural and Clinical Predictors of Cognitive Impairment After Surgical Treatment for Ruptured Cerebral Aneurysms","Structural and Clinical Predictors of Late Cognitive Impairment After Microsurgical Clipping of Ruptured Cerebral Aneurysms: A Retrospective Cohort With Prospective Assessment","SCOPE-aSAH","Inclusion Criteria:\n\n* Age ≥18 years at the time of aSAH.\n* Treatment by microsurgical clipping of a ruptured cerebral aneurysm.\n* Survival until study recruitment.\n* Ability to understand and sign informed consent.\n\nExclusion Criteria:\n\n* Non-aneurysmal subarachnoid hemorrhage.\n* Exclusively endovascular treatment.\n* Previous diagnosis of dementia.\n* Severe neurological or psychiatric disorders unrelated to aSAH with significant cognitive impact.\n* Absolute contraindication to MRI.\n* Severe aphasia preventing adequate neuropsychological evaluation.\n* Incomplete clinical data.\n* Inability to attend in-person assessment.",{"count":56,"type":21},150,"OBSERVATIONAL","This study investigates the clinical and structural predictors of long-term cognitive impairment in patients who underwent microsurgical clipping for aneurysmal subarachnoid hemorrhage. Using a retrospective cohort with prospective neuropsychological and MRI assessments, it aims to identify factors associated with late cognitive deficits and improve prognostic stratification, rehabilitation planning, and long-term patient care.",[60,61,62],"Subarachnoid Aneurysm Hemorrhage","Microsurgery","Cognitive Impairment",[64,65,62],"Aneurysmal Subarachnoid Hemorrhage","Aneurysm Clipping","2026-07-20",{"date":68,"type":38},"2026-07-23",{"date":70,"type":21},"2026-08",{"date":72,"type":21},"2029-12",{"name":44,"class":45},{"id":75,"slug":76,"hasResults":11,"nctId":77,"briefTitle":78,"officialTitle":79,"acronym":4,"eligibilityCriteria":80,"healthyVolunteers":81,"sex":17,"minAge":18,"maxAge":82,"enrollmentInfo":83,"targetDuration":4,"studyType":22,"phases":85,"briefSummary":87,"conditions":88,"keywords":92,"overallStatus":97,"whyStopped":4,"lastUpdateSubmitDate":98,"lastUpdatePostDateStruct":99,"startDateStruct":101,"completionDateStruct":103,"leadSponsor":105,"locationsCount":46},"100628017","influence-of-zirconia-abutments-on-peri-implant-tissues-in-single-tooth-restorations-100628017","NCT07456163","Influence of Zirconia Abutments on Peri-Implant Tissues in Single-Tooth Restorations","Potential Influence of Pre-fabricated and Customized Anatomical Zirconia Abutments in the Peri-implant Region for Single-tooth Implant-supported Prosthetic Restorations","Inclusion Criteria:\n\n1. Individuals aged 18 years or older;\n2. Participants in the Master's Thesis entitled: \"Dimensional Changes Following Different Alveolar Preservation Protocols in Posterior Regions: A Randomized Controlled Study\";\n3. Patients with implants and healing abutments from Bionnovation Biomedical in place at the time of prosthetic rehabilitation;\n4. Implants without surrounding bone loss;\n5. Signed informed consent form.\n\nExclusion Criteria:\n\n1. Patients with uncontrolled systemic diseases;\n2. Pregnant or lactating women;\n3. Smokers or former smokers;\n4. Undergoing orthodontic treatment;\n5. Using medications that interfere with bone healing, such as those for osteoporosis and bisphosphonates;\n6. Implants with bone loss or failed implants.",true,"70 Years",{"count":84,"type":21},71,[86],"NA","Objectives:\n\nTo compare the influence of pre-fabricated titanium abutments and customized milled zirconia abutments on implant biocompatibility and the peri-implant region, as well as on radiographic bone loss and oral health-related quality of life.\n\nDetailed Methodology:\n\nThis study is a randomized controlled clinical trial designed to evaluate the biological and clinical behavior of standardized titanium abutments compared with customized anatomical zirconia abutments in single implant-supported posterior restorations. The present investigation represents the prosthetic phase of a previously conducted randomized clinical trial that evaluated dimensional changes following different alveolar preservation protocols in posterior regions (CAAE: 59208422.8.0000.5418). In the previous phase, participants underwent tooth extraction and alveolar preservation procedures, followed by implant placement with Morse Taper (CM) implants (Biomorse XP, Bionnovation Biomedical) after a six-month healing period. After implant osseointegration, participants eligible for prosthetic rehabilitation will be randomly allocated to one of two parallel groups using a computer-generated randomization sequence (Sealedenvelope.com). The allocation ratio will be 1:1. Sample size calculation was performed using GPower software to ensure adequate statistical power. The intervention consists of prosthetic rehabilitation with either standardized titanium abutments (TiB group) or customized anatomical zirconia abutments (ZiT group), both supporting single zirconia crowns in posterior regions. All prosthetic and laboratory procedures will follow standardized clinical protocols. Clinical and laboratory assessments will be conducted at prosthesis delivery (baseline) and at 1-, 3-, 6-, and 12-month follow-up visits. Data collection will include peri-implant crevicular fluid (PICF) and biofilm sampling for biomolecular analysis, comprehensive periodontal clinical parameters, measurement of keratinized mucosa thickness, standardized periapical radiographs for marginal bone level assessment, and intraoral digital scanning for volumetric and soft tissue analysis. The primary objective is to compare peri-implant tissue stability and biological response between titanium and zirconia abutments. Secondary outcomes include clinical parameters, marginal bone level changes, and soft tissue dimensional stability over a 12-month follow-up period. This study aims to contribute to the understanding of how abutment material and design may influence peri-implant health and long-term tissue stability in posterior implant-supported restorations.",[89,90,91],"Peri-Implant Health","Implant Complication","Prosthesis and Implants",[93,94,95,96],"Dental Prosthesis","Connection, Dental Implant-Abutment","Dental Porcelain","Biofilm","RECRUITING","2026-03-13",{"date":100,"type":38},"2026-03-17",{"date":102,"type":38},"2025-04-30",{"date":104,"type":21},"2027-12-01",{"name":44,"class":45},{"id":107,"slug":108,"hasResults":11,"nctId":109,"briefTitle":110,"officialTitle":110,"acronym":4,"eligibilityCriteria":111,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":112,"targetDuration":4,"studyType":22,"phases":114,"briefSummary":115,"conditions":116,"keywords":122,"overallStatus":97,"whyStopped":4,"lastUpdateSubmitDate":127,"lastUpdatePostDateStruct":128,"startDateStruct":130,"completionDateStruct":132,"leadSponsor":134,"locationsCount":46},"100575487","effects-of-a-pulmonary-and-cardiovascular-rehabilitation-program-100575487","NCT06772922","Effects of a Pulmonary and Cardiovascular Rehabilitation Program","Inclusion Criteria:\n\n* Candidates for the pulmonary rehabilitation program: users diagnosed with chronic obstructive pulmonary disease (COPD), pulmonary emphysema, pulmonary fibrosis, asthma or other lung disease.\n* Candidates for the cardiovascular rehabilitation program: users diagnosed with acute myocardial infarction, myocardial revascularization surgery, coronary angioplasty, stable angina, valve replacement, chronic heart failure and who meet the criteria for phase III of cardiovascular rehabilitation.\n* Referral with medical clearance for rehabilitation\n\nExclusion Criteria:\n\n* Patients with any contraindication to aerobic or muscle-strengthening physical exercise, such as significant arrhythmias, untreated heart disease, myocarditis, recent or untreated pulmonary embolism, and uncontrolled systemic arterial hypertension, among other conditions.",{"count":113,"type":21},26,[86],"Non-communicable chronic diseases (NCDs) affect approximately 30% of the adult global population, significantly impacting respiratory function and quality of life. Pulmonary and cardiovascular rehabilitation has proven to be an effective therapeutic intervention for managing respiratory symptoms and cardiovascular and improving functional capacity in patients with chronic respiratory conditions. The objective of this study is to evaluate the effects of the pulmonary and cardiovascular rehabilitation program on users of the physical therapy service of CECOM of UNICAMP related to functional capacity, quality of life and respiratory variables after 3 months of the program. Candidates for the pulmonary rehabilitation program are users diagnosed with chronic obstructive pulmonary disease (COPD), pulmonary emphysema, pulmonary fibrosis, asthma or other lung disease. Candidates for the cardiovascular rehabilitation program are users diagnosed with: infarction (AMI), myocardial revascularization surgery, coronary angioplasty, stable angina, valve replacement, chronic heart failure and who meet the criteria for phase III of cardiovascular rehabilitation. They should be referred to physical therapy by the cardiologist with complementary exams and exercise test. The program's assessment will consist of: anamnesis, analysis and recording of complementary exams, physical assessment (weight, height, BMI, cardiac and pulmonary auscultation, blood pressure, heart rate, peripheral oxygen saturation, respiratory muscle strength), functional capacity (six-minute walk test) and quality of life (questionnaire). The program will include aerobic exercises on a treadmill or stationary bike with an intensity between 50-70% of the reserve HR, below the ischemic thresholds. It will also include peripheral muscle strength exercises for the upper and lower limbs, in addition to respiratory muscle training for lung disease patients.",[117,118,119,120,121],"Respiratory Muscle Weakness","Quality of Lifte","Dyspnea; Asthmatic","Dyspnea; Cardiac","Dyspnea",[123,124,125,126],"pulmonary rehabilitation","Non-communicable chronic diseases","cardiovascular disease","cardiac rehabilitation","2025-01-11",{"date":129,"type":38},"2025-01-14",{"date":131,"type":38},"2019-03-03",{"date":133,"type":21},"2025-12-20",{"name":44,"class":45},{"id":136,"slug":137,"hasResults":11,"nctId":138,"briefTitle":139,"officialTitle":140,"acronym":4,"eligibilityCriteria":141,"healthyVolunteers":11,"sex":17,"minAge":142,"maxAge":4,"enrollmentInfo":143,"targetDuration":4,"studyType":22,"phases":145,"briefSummary":147,"conditions":148,"keywords":153,"overallStatus":97,"whyStopped":4,"lastUpdateSubmitDate":156,"lastUpdatePostDateStruct":157,"startDateStruct":158,"completionDateStruct":160,"leadSponsor":162,"locationsCount":46},"100562279","phase-3-effects-of-topical-insulin-on-corneal-epithelium-healing-after-corneal-crosslinking-in-patients-with-keratoconus-100562279","NCT06601101","Effects of Topical Insulin on Corneal Epithelium Healing After Corneal Crosslinking in Patients With Keratoconus","Effects of Topical Insulin on Corneal Epithelium Healing After Corneal Crosslinking in Patients With Keratoconus: A Randomized Clinical Trial","Inclusion Criteria:\n\n* Patients with a diagnosis of keratoconus, indicated for corneal crosslinking\n\nExclusion Criteria:\n\n* Diabetes Mellitus\n* Severe dry eye\n* Limbal Stem Cell Deficiency\n* Glaucoma\n* Insulin or methylcellulose allergy","14 Years",{"count":144,"type":21},36,[146],"PHASE3","The cornea plays a fundamental role in vision, being a complex tissue essential for ocular health. In ophthalmological practice, there are situations such as corneal crosslinking, where damage to the corneal epithelium occurs. Crosslinking is a surgical procedure aimed at strengthening collagen bonds in the corneal stroma to prevent the progression of keratoconus, through the application of topical riboflavin followed by ultraviolet (UV-A) radiation. To enhance the effectiveness of riboflavin and UV-A radiation, the corneal epithelium needs to be removed, which can cause postoperative pain and discomfort, as well as increase the risk of complications such as infections, scarring, corneal opacities, perforations, and recurrent epithelial erosions. Several growth factors play a role in epithelial healing, and the discovery of insulin in the tear film and the presence of insulin and Insulin-Like Growth Factor (IGF-1) receptors in the cornea has raised the hypothesis that insulin may modulate the cornea's wound healing response. Since then, topical insulin has been used for various ocular pathologies, including dry eye disease, persistent epithelial defects, and neurotrophic ulcers. Based on this knowledge, studies have been developed, and promising results regarding the use of insulin in corneal healing have been reported, providing a scientific foundation for the realization of this project. The objective of this study is to evaluate the effect of insulin eye drops at a concentration of 50 IU\u002Fml on epithelial healing in non-diabetic patients undergoing epithelial debridement for corneal crosslinking. To this end, a randomized, double-masked clinical trial will be conducted with two groups, one being the control group, in which researchers will compare the epithelial healing rate in mm²\u002Fh between the insulin group and the placebo group, as the primary outcome. Patients diagnosed with keratoconus and with an indication for the crosslinking procedure, will be invited to participate. As a result of the study, it is expected to assess and quantify the impact of topical insulin on epithelial defect closure in patients undergoing crosslinking, compared to placebo. Topical insulin may contribute to early epithelial defect closure, control of inflammation, and prevention of complications that could significantly impact visual quality.",[149,150,151,152],"Keratoconus","Cornea Disease","Eye Diseases","Wound Heal",[154,155],"Topical Insulin","Crosslinking","2025-01-10",{"date":129,"type":38},{"date":159,"type":38},"2024-08-01",{"date":161,"type":21},"2025-10-01",{"name":44,"class":45},{"id":164,"slug":165,"hasResults":11,"nctId":166,"briefTitle":167,"officialTitle":167,"acronym":168,"eligibilityCriteria":169,"healthyVolunteers":11,"sex":170,"minAge":18,"maxAge":4,"enrollmentInfo":171,"targetDuration":4,"studyType":22,"phases":173,"briefSummary":174,"conditions":175,"keywords":177,"overallStatus":97,"whyStopped":4,"lastUpdateSubmitDate":181,"lastUpdatePostDateStruct":182,"startDateStruct":184,"completionDateStruct":186,"leadSponsor":188,"locationsCount":46},"100570741","phase-3-effect-of-dapaglifozin-on-myocardial-remodeling-of-breast-cancer-patients-treated-with-anthracycline-based-chemotherapy-100570741","NCT06711185","Effect of DAPAglifozin on MYOcardial Remodeling of Breast CANCER Patients Treated with Anthracycline Based Chemotherapy","DAPA-MYOCANCER","Inclusion Criteria:\n\n* Female\n* Over 18 years old\n* Breast cancer\n* Chemotherapy as treatment planning and programmed cumulative dose equivalent to 240 mg\u002Fm2 of doxorubicin.\n\nExclusion Criteria:\n\n* Contraindications for performing CMR exams, such as patients with pacemakers or cardiac defibrillators of any type, metal clips for cerebral aneurysms, cochlear implants, and ventriculoperitoneal bypass valves.\n* Inability to perform CMR due to claustrophobia.\n* Renal failure with a glomerular filtration rate \\\u003C 30 ml\u002Fmin\u002F1.73 m2.\n* Previous history of myocardial infarction, congestive heart failure, or myocardial revascularization, whether percutaneous or surgical.\n* Previous history of significant valvular heart disease.\n* Previous history of cardiomyopathies.","FEMALE",{"count":172,"type":21},80,[146],"Prospective, randomized, double-blind, controlled clinical trial to compare the effect of 9 months of treatment with dapagliflozin vs. placebo on anthracycline-induced cardiotoxicity in patients with breast cancer.",[176],"Breast Cancer",[178,179,180],"Dapagliflozin","Anthracyclines","chemotherapy induced cardiomyopathy","2024-11-26",{"date":183,"type":38},"2024-12-02",{"date":185,"type":38},"2024-01-30",{"date":187,"type":21},"2026-08-30",{"name":44,"class":45},{"id":190,"slug":191,"hasResults":11,"nctId":192,"briefTitle":193,"officialTitle":194,"acronym":4,"eligibilityCriteria":195,"healthyVolunteers":81,"sex":17,"minAge":18,"maxAge":196,"enrollmentInfo":197,"targetDuration":4,"studyType":57,"phases":4,"briefSummary":198,"conditions":199,"keywords":202,"overallStatus":97,"whyStopped":4,"lastUpdateSubmitDate":208,"lastUpdatePostDateStruct":209,"startDateStruct":211,"completionDateStruct":213,"leadSponsor":215,"locationsCount":46},"100550688","resistant-hypertension-an-open-complicated-cum-plicare-or-complex-cum-plexus-syndrome-100550688","NCT06450327","Resistant Hypertension An Open, Complicated (\"Cum Plicare\") or Complex (\"Cum Plexus\") Syndrome?","Resistant Hypertension An Open, Complicated (\"Cum Plicare\") or Complex (\"Cum Plexus\")","Inclusion Criteria:\n\n* men and women over 35 years of age diagnosed with resistant arterial hypertension (RH), in accordance with the latest international and national guidelines;\n* be able to understand, verbalize and answer questions;\n* agree to participate in the study and sign the Informed Consent Form;\n* after clearly understanding it;\n* be under regular follow-up at the UNICAMP Cardiovascular Pharmacology outpatient clinic for at least six months;\n* have proven adherence to non-pharmacological and pharmacological treatment;\n* women in the reproductive phase must be using a proven effective contraceptive method.\n\nExclusion Criteria:\n\n* clinical history or clinical symptoms of heart failure;\n* patients with dilated cardiomyopathies, valvular heart disease, pericardial disorders;\n* patients with cerebrovascular disease or peripheral arterial disease, nephropathies, liver diseases, smoking, autoimmune diseases and use of illicit substances;\n* any abnormal condition that may interfere with the results of the study or the health of the volunteer, as judged by the researcher;\n* women who are pregnant or intend to become pregnant;\n* current participation in another investigative study;\n* major depression or other relevant psychiatric disorders.","85 Years",{"count":172,"type":21},"Resistant arterial hypertension (RAH) is a complex and multifactorial syndrome, with hyperactivity of the sympathetic nervous system (SNS) and reduction of vagal activity being considered some of the main causes of refractoriness to treatment. Seen from the outside, it resembles a complicated (see lat. \"Cum plicate\") or complex disease (see lat. \"Cum plexus\"), Chaotic with the participation of several open systems. For example, in recent years some relationships have been demonstrated between the autonomic nervous systems, synaptic mediators, hormones, inflammatory and immune responses. However, these findings have not been investigated together and systematically. In the present project, we intend to establish and compare, in an integrated way, the clinical alterations present in RAH (resistant and refractory), hemodynamic variables, autonomous activity (sympathetic and baroreflex) and interactions with the neuroimmune-endocrine systems. To this end, we will test the hypothesis that resistant patients have greater damage to the autonomic nervous system (ANS) associated with exacerbated systemic and hormonal inflammatory profile, including SNA mediators (noradrenaline and acetylcholinesterase). This is also intended to determine the behavior (deterministic or chaotic) of the systems evaluated (mentioned above) in volunteers with RAH. Sample and methods: The sample space (calculated) will consist of 72 individuals, being: - 18 refractory hypertensive (HRT); II- 18 resistant hypertensive patients (HRfT); III- 18 controlled hypertensive (1-2 drugs) (CAH); and IV- 18 healthy normotensive individuals. This is a prospective, double-blind study (patient and professional-technician), paired (1 X 4), in which the 72 volunteers will be evaluated by the methods set out below. We will also have the chance to observe whether resistant and refractory hypertension share the same pathophysiological bases and clinical manifestations (\"deterministic-isolated or cardiovascular chaos\") by analyzing the patterns of cardiovascular variability (MAPA and Holter) (SpaceLabs, USA; DynaMap, Brazil), inflammatory and hormonal mediators (ELISA) in the resistant hypertension - RHT and refratary hypertension - HfRT groups. Central pressure (CP) and arterial stiffness (pulse wave velocity, VOP) (Sphymocor, ATCor, USA) will also be assessed. Healthy normotensive (NT) and controlled hypertension (CAH) will be evaluated in an identical way to control the other groups. Perspectives: The findings will improve the clinical knowledge based on pathophysiology about Resistant Hypertension and, mainly, the bases of pharmacological treatment and with implantable devices (stimulation of baroreceptors and sympathetic denervation) used in this condition.",[200,201],"Hypertension","Resistant Hypertension",[203,204,205,206,207],"autonomic nervous system","resistant hypertension","arterial hypertension","refractory hypertension","baroreceptors","2024-08-28",{"date":210,"type":38},"2024-08-29",{"date":212,"type":38},"2024-08-27",{"date":214,"type":21},"2026-12-30",{"name":44,"class":45},""]